2cureX AB

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div yield, %

17.57%

Shrs. gr., 5y

13.03%

Rev. gr., 5y

-54.18%

Revenues

Net income

CFO

Dividend

Jun 27, 20250.084 SEK/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Based in Copenhagen, Denmark, 2cureX AB (publ) is a European medtech firm established in 2006. The company's core offering is IndiTreat, an in-vitro diagnostic test designed to forecast how cancer patients will respond to or resist various drug treatments, thereby guiding clinicians in selecting the most effective therapy. Additionally, 2cureX is actively advancing IndiTreat through clinical programs targeting a range of cancers, including breast, colorectal, ovarian, and pancreatic types.

URL

https://www.2curex.com/

IPO date

Nov 24, 2017

Employees

Domiciled in

Incorporated in

Valuation

No data to show